Compare DexCom, Inc. (DXCM) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs STMicroelectronics NV — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while STMicroelectronics NV trades at $52.03 (market cap $48.14B). The key difference: STMicroelectronics NV is the larger of the two by market cap, and STMicroelectronics NV pays a 0.68% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and STMicroelectronics NV for 64 Days on average.
| DXCM | STM | |
|---|---|---|
Market Cap | $31.86B | $48.14B |
Volume | 3,607,070 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $92.34 | $79.91 |
52-Week Low | $54.84 | $21.20 |
Typical Hold Time | 62 Days | 64 Days |
Enterprise Value | $31.32B | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
STM is trading at $52.06, down 7.33% over 24 hours amid broader tech sector pressure. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a $77.31 consensus price target. Recent earnings have been volatile with two misses and one beat in the last three quarters, while the company maintains strong cash flow generation of $555 million in 2025. STM is positioning for AI data-center revenue growth, targeting over $2 billion by 2027, with recent product launches in automotive imaging and edge AI partnerships.
The outlook remains cautiously optimistic given STM's strategic positioning in AI infrastructure and automotive semiconductors, though near-term margin pressures from facility transitions and competitive dynamics pose risks. The 48% upside to consensus target suggests Wall Street sees recovery potential, but investors should monitor execution on AI revenue targets and margin improvement through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
